Observational studyMedicine2018
Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.
Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis.Frontiers in public health · 2023Pooled it
- Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV.The Journal of infectious diseases · 2019Trial
- PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Lipid Profile Differences in HIV-Infected Populations With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Chronic diseases and translational medicine · 2026Article
- Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide.Open forum infectious diseases · 2023Article
- Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV.BMC infectious diseases · 2023Article
- Dosage of Dual-Protein Nutrition Differentially Impacts the Formation of Atherosclerosis inNutrients · 2022Article
- Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Review
- A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil.AIDS (London, England) · 2022Observational
- Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop.AIDS research and human retroviruses · 2021Article
- Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).EClinicalMedicine · 2021Article
- HIV and Antiretroviral Therapy Are Independently Associated with Cardiometabolic Variables and Cardiac Electrical Activity in Adults from the Western Cape Region of South Africa.Journal of clinical medicine · 2021Article
- NASH in HIV.Current HIV/AIDS reports · 2020Review
- Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Obesity and Weight Gain in Persons with HIV.Current HIV/AIDS reports · 2020 · on this mapReview
- Article
- Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.PloS one · 2019Article
- Non-Alcoholic Fatty Liver Disease and Its Sarco-Metabolic Correlates in People Living with Human Immunodeficiency Virus Infection.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevalence and risk factors for hepatic steatosis (HS) in the human immunodeficiency virus (HIV)-positive population of western countries are controversially discussed and potentially confounded by coinfection with viral hepatitis. Significant HS (more than 10% of hepatocytes) can be accurately assessed using controlled attenuation parameter (CAP) determination. Aim of this study was to assess prevalence and factors associated with significant HS in HIV monoinfected patients.A total of 364 HIV-infected patients (289 monoinfected) were included in this prospective, cross-sectional study. All patients underwent CAP determination. Steatosis was classified as S1 (significant steatosis) with CAP > 238 dB/m, S2 with CAP > 260 dB/m, and S3 with CAP > 292 dB/m. Multivariable logistic regression analyses were performed to assess the factors associated with HS in this cohort.Significant HS was detected in 118 monoinfected patients (149 in the total cohort). In the total cohort as well as in the monoinfected patients alone, HS grade distribution showed a similar pattern (S1:29%, S2:34%, and S3:37%). Interestingly, patients with HS had a longer history of HIV infection and combined antiretroviral therapy (cART). Interalia, age, gender, ethnicity, and metabolic factors were strongly associated with HS, while body mass index (BMI), triglyceride, and glycated hemoglobin (HbA1c) levels were independently associated with significant HS.HS is highly prevalent among HIV monoinfected patients. Although metabolic risk factors, such as obesity and poorly controlled diabetes, are independently associated with HS in HIV monoinfected patients, cART and control of HIV seem to play an indirect role in the development of HS, probably through the return-to-health effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.